ArticleJAMA network open2025
Cord Blood Appetite Hormones and Early-Life Growth and Childhood Adiposity in the ENVIRONAGE Cohort.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Understanding early-life origins of increased body mass is crucial because childhood obesity increases the risk of later development of obesity and related metabolic disorders. Appetite hormones have been investigated in relation to fat accumulation in adults, but little is known about the association between cord blood levels of these hormones and obesity-related outcomes in early childhood. Objective: To examine whether cord blood appetite hormone levels are associated with early-life growth trajectories and childhood adiposity. Design, Setting, and Participants: This prospective birth cohort study was conducted within the Environmental Influence on Early Aging (ENVIRONAGE) birth cohort, with follow-up data collected at 4 to 6 years of age. The study includes children from a population-based cohort in Belgium recruited between January 1, 2010, and December 31, 2016, with available cord blood appetite hormone levels and participating in follow-up visits. Exposures: Cord blood levels of glucagon-like peptide 1 (GLP-1), peptide tyrosine tyrosine (PYY), pancreatic polypeptide (PP), and leptin. Main Outcomes and Measures: Adiposity peak, anthropometric measures at 4 to 6 years of age (waist to height ratio and body mass index z score), and rapid growth and slow growth from birth to 6, 12, and 24 months. Results: A total of 325 children (median [IQR] age, 4.49 [4.04-4.95] years; 151 [46.5%] male) were studied. Analyses were performed in 2 subgroups based on availability of appetite hormones: 226 children with cord blood PP and leptin (median [IQR] age at follow-up, 4.5 [4.3-4.7] years; 108 [47.8%] male) and 229 children with cord blood PYY and GLP-1 (median [IQR] age at follow-up, 4.5 [4.3-4.8] years; 98 [42.8%] male). PYY levels were positively associated with the adiposity peak (β = 0.14; 95% CI, 0.01-0.27). PYY and PP levels were associated with an higher risk of rapid growth in the first 2 years of life (odds ratio [OR], 1.71; 95% CI, 1.03-2.84; OR, 1.65; 95% CI, 1.21-2.27, respectively). Leptin levels showed an inverse association with rapid growth (OR, 0.43; 95% CI, 0.27-0.66). PYY and PP levels were associated with a higher body mass index z score at 4 to 6 years of age (β = 0.16; 95% CI, 0.04-0.30; β = 0.17; 95% CI, 0.004-0.34, respectively). Conclusions and Relevance: In this cohort study of 325 children, cord blood appetite hormone levels were associated with early-life growth and adiposity, suggesting that appetite hormones may influence childhood growth and body composition trajectory from birth onward.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.